Boston Scientific Corp (BSX) has a current Price-to-Book (P/B) ratio of 6.00. Compared to its 3-year average P/B ratio of 5.53, the current P/B ratio is approximately 8.51% higher. Relative to its 5-year average P/B ratio of 4.74, the current P/B ratio is about 26.56% higher. Boston Scientific Corp (BSX) has a Forward Free Cash Flow (FCF) yield of approximately 2.72%. Compared to its 3-year average FCF yield of 1.83%, the current FCF yield is approximately 48.80% lower. Relative to its 5-year average FCF yield of 1.88%, the current FCF yield is about 45.25% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BSX competitors is 5.50, providing a benchmark for relative valuation. Boston Scientific Corp Corp (BSX.N) exhibits a P/S ratio of 6.47, which is 17.52% above the industry average. Given its robust revenue growth of 15.90%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BSX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BSX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BSX currently overvalued or undervalued?

What is Boston Scientific Corp (BSX) fair value?

BSX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Boston Scientific Corp (BSX) is between 63.78 to 82.47 according to relative valuation method.

How does BSX's valuation metrics compare to the industry average?

The average P/S ratio for BSX's competitors is 5.50, providing a benchmark for relative valuation. Boston Scientific Corp Corp (BSX) exhibits a P/S ratio of 6.47, which is 17.52% above the industry average. Given its robust revenue growth of 15.90%, this premium appears unsustainable.

What is the current P/B ratio for Boston Scientific Corp (BSX) as of Mar 03 2026?

As of Mar 03 2026, Boston Scientific Corp (BSX) has a P/B ratio of 6.00. This indicates that the market values BSX at 6.00 times its book value.

What is the current FCF Yield for Boston Scientific Corp (BSX) as of Mar 03 2026?

As of Mar 03 2026, Boston Scientific Corp (BSX) has a FCF Yield of 2.72%. This means that for every dollar of Boston Scientific Corp's market capitalization, the company generates 2.72 cents in free cash flow.

What is the current Forward P/E ratio for Boston Scientific Corp (BSX) as of Mar 03 2026?

As of Mar 03 2026, Boston Scientific Corp (BSX) has a Forward P/E ratio of 28.52. This means the market is willing to pay $28.52 for every dollar of Boston Scientific Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Boston Scientific Corp (BSX) as of Mar 03 2026?

As of Mar 03 2026, Boston Scientific Corp (BSX) has a Forward P/S ratio of 6.47. This means the market is valuing BSX at $6.47 for every dollar of expected revenue over the next 12 months.

BSX Valuation